Lumos Pharma, Inc.
LUMO · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $726 | $488 | $165 | $826 |
| % Growth | 48.8% | 195.8% | -80% | – |
| Cost of Goods Sold | $0 | $2 | $2 | $18 |
| Gross Profit | $726 | $486 | $163 | $808 |
| % Margin | 100% | 99.6% | 98.8% | 97.8% |
| R&D Expenses | $4,153 | $4,629 | $7,248 | $6,657 |
| G&A Expenses | $4,213 | $3,682 | $3,779 | $4,173 |
| SG&A Expenses | $4,213 | $3,680 | $3,777 | $4,155 |
| Sales & Mktg Exp. | $0 | -$2 | -$2 | -$18 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8,366 | $8,309 | $11,025 | $10,812 |
| Operating Income | -$7,640 | -$7,823 | -$10,862 | -$10,004 |
| % Margin | -1,052.3% | -1,603.1% | -6,583% | -1,211.1% |
| Other Income/Exp. Net | $173 | $272 | $421 | $547 |
| Pre-Tax Income | -$7,467 | -$7,551 | -$10,441 | -$9,457 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7,467 | -$7,551 | -$10,441 | -$9,457 |
| % Margin | -1,028.5% | -1,547.3% | -6,327.9% | -1,144.9% |
| EPS | -0.9 | -0.93 | -1.29 | -1.17 |
| % Growth | 3.2% | 27.9% | -10.3% | – |
| EPS Diluted | -0.9 | -0.93 | -1.29 | -1.17 |
| Weighted Avg Shares Out | 8,327 | 8,113 | 8,105 | 8,102 |
| Weighted Avg Shares Out Dil | 8,327 | 8,113 | 8,105 | 8,102 |
| Supplemental Information | – | – | – | – |
| Interest Income | $168 | $70 | $158 | $293 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $2 | $2 | $18 |
| EBITDA | -$7,640 | -$7,821 | -$10,860 | -$9,986 |
| % Margin | -1,052.3% | -1,602.7% | -6,581.8% | -1,209% |